...
首页> 外文期刊>Phytotherapy research: PTR >Berberine-induced haemolysis revisited: Safety of Rhizoma coptidis and cortex phellodendri in chronic haematological diseases
【24h】

Berberine-induced haemolysis revisited: Safety of Rhizoma coptidis and cortex phellodendri in chronic haematological diseases

机译:再谈小碱诱导的溶血:黄连和黄柏在慢性血液病中的安全性

获取原文
获取原文并翻译 | 示例

摘要

Two commonly used berberine-containing Chinese herbs, Rhizoma coptidis (RC) and Cortex phellodendri (CP), have been banned in Singapore for the past three decades due to implication of berberine in aggravating jaundice and kernicterus in neonates with glucose-6-phosphate dehydrogenase deficiency. Here we conducted a single arm, phase I/II clinical study on Chinese herbal medicine for patients with chronic cytopenic haematological conditions and we analysed a subset of 20 patients who also had RC, CP or both in their herbal concoction. We found no organ toxicity or electrolyte imbalance in these 20 patients where RC was administered for 1055 patient-days and CP for 1252 patient-days. In three patients with thalassemia intermedia, transient elevation in serum bilirubin level was observed but this was not associated with any aggravation of anaemia or liver dysfunction. A review of the literature found conflicting evidence of varying levels either supporting or refuting the allegation of neonatal jaundice and kernicterus caused by berberine. There were, however, very few clinical reports of adverse reaction attributable to RC or CP in oral TCM concoction. We conclude that based on traditional dosage and indication, the use of RC and CP in oral concoction is safe.
机译:在过去的三十年中,新加坡已禁止使用两种常用的含有黄连素的中草药(黄连)和黄柏(CP),这是因为黄连素可能会通过葡萄糖-6-磷酸脱氢酶加重新生儿黄疸和角膜炎。不足。在这里,我们对患有慢性血细胞减少症的血液病患者进行了单臂I / II期中草药临床研究,我们分析了20例同时在药草中同时患有RC,CP或两者兼有的患者。我们发现这20例患者均未发生器官毒性或电解质失衡,其中RC进行了1055个患者-天,CP进行了1252个患者-天。在三例地中海贫血中度患者中,观察到血清胆红素水平短暂升高,但这与贫血或肝功能障碍的恶化无关。对文献的审查发现,不同水平的相互矛盾的证据支持或反驳了由小ber碱引起的新生儿黄疸和核黄疸的指控。然而,很少有临床报告称口服中药混合可归因于RC或CP引起的不良反应。我们得出结论,根据传统的剂量和适应症,在口服药中使用RC和CP是安全的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号